-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
AbbVie delivered strong Q1 2026 results with adjusted EPS of $2.65 (+7.7% Y/Y) slightly below the consensus of $2.67 due to $0.41 unfavorable impact from acquired IPR&D and milestones expense. Net revenues of $15.002B (+12.4% Y/Y) beat expectations by $280M, reflecting robust growth across key therapeutic areas. The successful transition from Humira to newer immunology assets continues to validate AbbVie's strategic positioning, with Skyrizi revenues of $4.483B (+30.9%) and Rinvoq revenues of $2.119B (+23.3%) substantially offsetting Humira's decline to $688M (-38.6%). The company raised its 2026 adjusted EPS guidance to $14.08-$14.28 from $13.96-$14.16, which includes the Q1 IPR&D impact. We believe the diversified growth platform demonstrates continued strength, with the immunology franchise generating $7.290B (+16.4%) and neuroscience portfolio delivering $2.875B (+26.0%). In our view, AbbVie's commitment to pipeline expansion through strategic investments positions the company well for sustained growth.